Literature DB >> 1581493

A class of phase II designs with three possible outcomes.

B E Storer1.   

Abstract

In the Phase II design of Fleming (1982, Biometrics 38, 143-151), the possible outcomes are to reject H1:p less than or equal to p1 or to reject H2: p greater than or equal to p2, where p1 less than p2. The design is constrained by specifying that Pr(reject H1[p1) less than or equal to alpha and Pr(reject H2[p2) less than or equal to beta. This can lead to some ambiguity as to the appropriate practical decision at the end of the trial, as the confidence region for p may include a substantial part of the interval between p1 and p2. We propose a class of designs wherein an allowable outcome is not to reject either H1 or H2. An additional constraint is placed on the design by specifying Pr(reject Hj[pm) less than or equal to gamma (j = 1, 2), where p1 less than pm less than p2. This type of design can provide a more realistic basis for decision making following the trial, although traditional values of alpha and/or beta need to be viewed from a somewhat different perspective in order to maintain a reasonable sample size. Some optimal single-stage and sequential multistage designs are presented.

Mesh:

Year:  1992        PMID: 1581493

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  1 in total

1.  Optimal multistage designs for randomised clinical trials with continuous outcomes.

Authors:  James M S Wason; Adrian P Mander; Simon G Thompson
Journal:  Stat Med       Date:  2011-12-05       Impact factor: 2.373

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.